• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

FDA complicates 'chaotic' federal COVID-19 response with pledge to resume...

cafead

Administrator
Staff member
  • cafead   Jul 13, 2020 at 11:32: PM
via The FDA's usual facility inspections have been on hold for months because of COVID-19—and pharma isn't happy. Now, after hearing calls from all levels of the drug industry, the agency says it will kick off inspections again. But it's far from a full-scale restart.

The FDA will resume "prioritized" domestic manufacturing inspections the week of July 20 after a four-month moratorium on most on-site walkthroughs, FDA Commissioner Stephen Hahn said in a release Friday.

article source